| Absolute treatment effects for the primary outcome and all-cause mortality in the cardiovascular outcome trials of new antidiabetic drugs: a meta-analysis of digitalized individual patient data | Acta Diabetologica | |
| Subcutaneous infusion of exenatide and cardiovascular outcomes in type 2 diabetes: a non-inferiority randomized controlled trial | Nature Medicine | 2021 |
| Necessity of Baseline Diabetic Autonomic Neuropathy Screening to Start Cardiovascular Safety Outcome Trials: A Focus on Antidiabetic Agents and Autonomic Neurointegrity | Bengal Physician Journal | 2022 |
| Reliable choice in therapy of type 2 diabetes mellitus: focus on alogliptin | Meditsinskiy Sovet | 2019 |
| CARDIOVASCULAR SAFETY OF GLIPTINS. FOCUS ON ALOGLIPTIN | Meditsinskiy Sovet | 2017 |
| Integrated Diabetes Care in Hong Kong: From Research to Practice to Policy | | 2017 |
| Placebo Effects and Placebo Control in Clinical Trials | | 2016 |
| Regulatory Considerations for Early Clinical Development of Drugs for Diabetes, Obesity, and Cardiometabolic Disorders | | 2015 |
| Development of therapeutic options on type 2 diabetes in years: Glucagon-like peptide-1 receptor agonist's role intreatment; from the past to future | World Journal of Diabetes | 2019 |
| A Review of Phosphate Binders in Chronic Kidney Disease: Incremental Progress or Just Higher Costs? | Drugs | 2017 |
| The Genesis of Cardiovascular Safety Regulatory Landscapes for New Antidiabetic Drugs for Type 2 Diabetes | | 2017 |
| What Is the Question? | | 2015 |
| Identifying and Addressing Safety Signals in Clinical Trials: Some Issues and Challenges | Lecture Notes in Statistics | 2013 |
| Recent developments in GLP-1RA therapy: A review of the latest evidence of efficacy and safety and differences within the class | Diabetes, Obesity and Metabolism | 2021 |
| Heart failure at the crossroads of cardiology and diabetology | Diabetes Research and Clinical Practice | 2021 |
| Effects of anti-diabetes medications on cardiovascular and kidney outcomes in Asian patients with type 2 diabetes: a rapid evidence assessment and narrative synthesis | Expert Opinion on Drug Safety | 2021 |
| Cardiovascular and kidney outcomes of linagliptin treatment in older people with type 2 diabetes and established cardiovascular disease and/or kidney disease: A prespecified subgroup analysis of the randomized, placebo-controlled CARMELINA® trial | Diabetes, Obesity and Metabolism | 2020 |
| Treatment paradigm shifting implications of recent cardiovascular outcome trials: Core insights on the brink of the 2020ies | Diabetes Research and Clinical Practice | 2020 |
| Effectiveness of sodium-glucose co-transporter-2 inhibitors on ischaemic heart disease | Diabetes, Obesity and Metabolism | 2020 |
| Advances in the management of diabetes: therapies for type 2 diabetes | Postgraduate Medical Journal | 2020 |
| The Effects of DPP-4 Inhibitors, GLP-1RAs, and SGLT-2/1 Inhibitors on Heart Failure Outcomes in Diabetic Patients With and Without Heart Failure History: Insights From CVOTs and Drug Mechanism | Frontiers in Endocrinology | 2020 |
| Effects of Sodium-glucose Cotransporter 2 Inhibitors on Amputation, Bone Fracture, and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus Using an Alternative Measure to the Hazard Ratio | Clinical Drug Investigation | 2019 |
| Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial | JAMA - Journal of the American Medical Association | 2019 |
| Heart Failure End Points in Cardiovascular Outcome Trials of Sodium Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Critical Evaluation of Clinical and Regulatory Issues | Circulation | 2019 |
| Renal Effects of Sodium-Glucose Co-Transporter Inhibitors | American Journal of Cardiology | 2019 |
| Diabetes Mellitus and Cardiovascular Disease | Arteriosclerosis, Thrombosis, and Vascular Biology | 2019 |
| The Discovery and Development of Liraglutide and Semaglutide | Frontiers in Endocrinology | 2019 |
| Cardiovascular Protection with Anti-hyperglycemic Agents | American Journal of Cardiovascular Drugs | 2019 |
| Lower rates of cardiovascular events and mortality associated with liraglutide use in patients treated with basal insulin: A DEVOTE subanalysis (DEVOTE 10) | Diabetes, Obesity and Metabolism | 2019 |
| Evidence-Based Cardiovascular Risk Management in Diabetes | American Journal of Cardiovascular Drugs | 2019 |
| Meta-analyses of the effects of DPP-4 inhibitors, SGLT2 inhibitors and GLP1 receptor analogues on cardiovascular death, myocardial infarction, stroke and hospitalization for heart failure | Diabetes Research and Clinical Practice | 2019 |
| Type 2 diabetes and the kidney: Insights from cardiovascular outcome trials | Diabetes, Obesity and Metabolism | 2019 |
| Regulatory Considerations for Early Clinical Development of Drugs for Diabetes, Obesity, Nonalcoholic Steatohepatitis (NASH) and Other Cardiometabolic Disorders | | 2019 |
| Advances in reducing cardiovascular risk in the management of patients with type 2 diabetes mellitus | Chronic Diseases and Translational Medicine | 2019 |
| Time-Matched Evaluation of Cardiovascular Risks Associated with Drugs for Type 2 Diabetes Mellitus | Clinical Drug Investigation | 2019 |
| Real-world prevalence of the inclusion criteria for the LEADER trial: Data from a national general practice network | Diabetes, Obesity and Metabolism | 2019 |
| Review of the cardiovascular safety of dipeptidyl peptidase-4 inhibitors and the clinical relevance of the CAROLINA trial | BMC Cardiovascular Disorders | 2019 |
| Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes | Current Cardiology Reports | 2019 |
| New Agents for the Treatment of Type 2 Diabetes | Critical Care Clinics | 2019 |
| Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial | JAMA - Journal of the American Medical Association | 2019 |
| Challenges and Opportunities Associated with Incorporating New Evidence of Drug-Mediated Cardioprotection in the Economic Modeling of Type 2 Diabetes: A Literature Review | Diabetes Therapy | 2019 |
| Renal Effects of Sodium-Glucose Co-Transporter Inhibitors | American Journal of Medicine | 2019 |
| Optimal Non-invasive Strategies to Reduce Recurrent Atherosclerotic Cardiovascular Disease Risk | Current Treatment Options in Cardiovascular Medicine | 2019 |
| Cardiologist as a cardiometabolic specialist | Journal of Clinical Hypertension | 2019 |
| Cardiovascular risks associated with dipeptidyl peptidase-4 inhibitors monotherapy compared with other antidiabetes drugs in the Japanese population: A nationwide cohort study | Pharmacoepidemiology and Drug Safety | 2019 |
| Class effect for SGLT-2 inhibitors: a tale of 9 drugs | Cardiovascular Diabetology | 2019 |
| SGLT-2 Inhibitors and Peripheral Artery Disease: A Statistical Hoax or Reality? | Current Problems in Cardiology | 2019 |
| Developing, Planning and Conducting an Interim Analysis: Lessons From the DEVOTE Cardiovascular Outcomes Trial (Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Patients With Type 2 Diabetes at High Risk of Cardiovascular Events) | Therapeutic Innovation and Regulatory Science | 2019 |
| The European Medicines Agency's approval of new medicines for type 2 diabetes | Diabetes, Obesity and Metabolism | 2018 |
| The place of gliclazide MR in the evolving type 2 diabetes landscape: A comparison with other sulfonylureas and newer oral antihyperglycemic agents | Diabetes Research and Clinical Practice | 2018 |
